• Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40...
Read more• 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, ...
Read more• First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna®both in front-line and second-line...
Read moreFinal Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival...
Read moreGlaxoSmithKline and Innoviva, Inc announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the...
Read more• Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension ...
Read morePfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and...
Read moreGSK presented new data for its meningococcal group B vaccine, Bexsero®,1 comparing safety...
Read moreSwedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life therapy,...
Read moreSwedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life therapy,...
Read morePharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
© 2017 Copyright © Valuemediaservices 2017 All rights reserved.